AbbVie announced that the European Commission (EC) has approved Rinvoq (upadacitinib; 15 mg tablet and weight-based 1 mg/mL oral solution) for the treatment of active polyarticular juvenile idiopathic… read more.
In an Arthritis & Rheumatology analysis of data on 60,980 US adults with autoimmune rheumatic conditions who developed COVID-19 between December 2020 and August 2024, those who received booster or… read more.
Roivant announced that the FDA has approved LISRAYA (brepocitinib) 30 mg for the treatment of adults with dermatomyositis (DM). LISRAYA is a pill taken once daily. DM is… read more.
An experimental cancer drug could stop osteoporosis and help women stay slim after the menopause – according to new research from the University of East Anglia. A study… read more.
Monash University researchers have reviewed existing evidence and concluded that most shoulder problems get better with self-management, education and time, challenging widespread clinical reliance on early imaging and… read more.
Regeneron Pharmaceuticals, Inc. announced the FDA has granted approval for Pasatru (garetosmab-grts) to reduce formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans… read more.
A new study published in Diabetes Care finds that bone loss alone does not explain the increased fracture risk observed in some older adults with type 2 diabetes. The article, “Type… read more.
The new drug is a starting point for therapies that treat OA at its source. Osteoarthritis (OA) is a chronic, painful joint disease and a leading cause of… read more.
The MHRA has approved Romvimza (vimseltinib ) to treat adult patients with tenosynovial giant cell tumour (TGCT) when it impacts movement or where surgery is not an option. TGCT (Giant cell… read more.
Neck and back pain could be caused by changes in gene activity that trigger the breakdown of the spine’s natural shock absorbers, new research suggests. Findings from a… read more.
New research by UCLA Health found GLP-1 medications may reduce the risk of serious fractures for adults with type 2 diabetes. Adults with type 2 diabetes and obesity… read more.
BioMarin Pharmaceutical Inc. announced that the U.S. Food and Drug Administration has accepted the company’s supplemental New Drug Application for Voxzogo (vosoritide) for full approval in children with… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
